ERSP targets sexual supplement
This article was originally published in The Tan Sheet
The Daily Wellness Company, producer of the sexual supplement ArginMax, has not responded to an initial inquiry regarding claims made in print advertising for the product, the Electronic Retailing Self-Regulation Program (ERSP) says. The claims in question include a statement touting ArginMax as the "only scientifically validated, natural nutritional supplement formula for sexual performance and enjoyment." The producers of the supposed sexual enhancer also assert ArginMax provides "88% improved ability to maintain erection[s]" and "71% improved level of sexual desire." According to ERSP protocol, Daily Wellness will be expected to provide substantiation for its core claims by Nov. 4 before ERSP refers the matter to the appropriate government agency...
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.